Parnassin

Parnassin is a novel therapeutic tetrapeptide derived from Parnassius bremeri transcriptome data, predicted to possess anti-microbial activity. It is being investigated as a potential treatment for atopic dermatitis (AD). Parnassin exerts its therapeutic effects by inhibiting the JAK2 and p38 MAPK signaling kinases, which in turn suppresses the activity of their downstream transcription factor STAT1. This immunomodulatory action leads to a reduction in the gene expression of Th2-type chemokines CCL17 and CCL22, as well as pruritus-inducing cytokines TSLP and IL-31. Preclinical studies in a DNCB-induced AD mouse model have shown that topical administration of parnassin improves skin lesions and symptoms, such as epidermal thickening and mast cell infiltration, without affecting body weight or spleen size/weight, suggesting a safer profile compared to existing treatments like dexamethasone.